OctaGenix
OctaGenix Limited is a privately-owned UK-based biopharmaceutical company specializing in oncology, obesity, infection control, viral diseases, medical cannabis, drug delivery systems, and orphan drugs. The company focuses on introducing innovative generics of high-cost orphan drugs, biosimilars, and unlicensed special medicines to global markets, aiming to improve patient access, management, and reduce healthcare inequalities. OctaGenix collaborates closely with the NHS, MHRA, and NICE to provide cost-effective, high-quality pharmaceuticals and invests in AI and medical technologies to enhance patient care and pharmacoeconomic performance. Their business model emphasizes patient-centric solutions, strategic partnerships, and delivering affordable, clinically effective treatments to support healthcare systems worldwide.
OctaGenix
OctaGenix Limited is a privately-owned UK-based biopharmaceutical company specializing in oncology, obesity, infection control, viral diseases, medical cannabis, drug delivery systems, and orphan drugs. The company focuses on introducing innovative generics of high-cost orphan drugs, biosimilars, and unlicensed special medicines to global markets, aiming to improve patient access, management, and reduce healthcare inequalities. OctaGenix collaborates closely with the NHS, MHRA, and NICE to provide cost-effective, high-quality pharmaceuticals and invests in AI and medical technologies to enhance patient care and pharmacoeconomic performance. Their business model emphasizes patient-centric solutions, strategic partnerships, and delivering affordable, clinically effective treatments to support healthcare systems worldwide.